2022
Vaccination in pediatric solid organ transplant: A primer for the immunizing clinician
Chen JK, Cheng J, Liverman R, Serluco A, Corbo H, Yildirim I. Vaccination in pediatric solid organ transplant: A primer for the immunizing clinician. Clinical Transplantation 2022, 36: e14577. PMID: 34997642, DOI: 10.1111/ctr.14577.Peer-Reviewed Original ResearchConceptsVaccine-preventable illnessesPediatric solid organ transplant recipientsSolid organ transplant recipientsPediatric solid organ transplantCorrect immunization schedulesPrevention's Advisory CommitteeOrgan transplant recipientsSolid organ transplantsInfectious Diseases SocietyTime of transplantTransplant recipientsDiseases SocietyVaccine recommendationsIncomplete immunizationImmunization scheduleAntibody titersInadequate responseOrgan transplantsElevated riskPreventable illnessMultiple guidelinesVaccine managementRapid catchDisease controlAmerican Society
2020
Who is at risk of 13-valent conjugated pneumococcal vaccine failure?
Yildirim M, Keskinocak P, Pelton S, Pickering L, Yildirim I. Who is at risk of 13-valent conjugated pneumococcal vaccine failure? Vaccine 2020, 38: 1671-1677. PMID: 31974018, DOI: 10.1016/j.vaccine.2019.12.060.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseVaccine failureIPD casesVaccine serotypesDiagnosis of IPDHigh vaccine coverage ratesPneumococcal conjugate vaccineVaccine coverage ratesUnderlying risk factorsYears of ageMonths of agePneumococcal pneumoniaImmunization PracticesVaccine scheduleConjugate vaccinePneumococcal diseasePrimary dosesClinical presentationImmunization scheduleSerotype 19ACourse of immunisationRisk factorsComorbiditiesStudy periodPassive surveillance
2018
1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
Yildirim I, Little B, Shea K, Pelton S, Massachusetts M. 1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease. Open Forum Infectious Diseases 2018, 5: s441-s442. PMCID: PMC6253418, DOI: 10.1093/ofid/ofy210.1261.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseStreptococcus pneumoniaeIPD casesPneumococcal diseaseVaccine serotypesIncidence of IPDCommon clinical presentationIntroduction of PCV13Pneumococcal conjugate vaccineOverall mortality rateChildhood immunization scheduleSickle cell diseaseYears of ageEnhanced surveillance systemIPD incidenceCommon comorbiditiesConjugate vaccineMassachusetts childrenClinical presentationImmunization scheduleCurrent epidemiologyCNS diseaseHematologic malignanciesCell diseaseClinical data2555. Predicting Risk of Breakthrough Invasive Pneumococcal Disease in Children After 13-Valent Pneumococcal Conjugate Vaccination
Yildirim M, Pelton S, Keskinocak P, Yildirim I. 2555. Predicting Risk of Breakthrough Invasive Pneumococcal Disease in Children After 13-Valent Pneumococcal Conjugate Vaccination. Open Forum Infectious Diseases 2018, 5: s68-s69. PMCID: PMC6252819, DOI: 10.1093/ofid/ofy209.163.Peer-Reviewed Original ResearchPCV13 vaccinationNonvaccine serotypesIncomplete vaccinationThirteen-valent pneumococcal conjugate vaccineDose of PCV7Pneumococcal conjugate vaccinationInvasive pneumococcal diseaseChildhood immunization scheduleCases of IPDStreptococcus pneumoniae isolatesYears of ageEnhanced surveillance systemConjugate vaccinationPCV13 immunizationVT-IPDPneumococcal pneumoniaIPD casesConjugate vaccineIncomplete immunizationPneumococcal diseasePneumococcal infectionComorbid conditionsImmunization scheduleComplete immunizationClinical data
2017
Invasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13
Yildirim I, Little B, Pelton S. Invasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13. Open Forum Infectious Diseases 2017, 4: s67-s67. DOI: 10.1093/ofid/ofx162.159.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseYears of ageNonvaccine serotypesSpeaker honorariaStreptococcus pneumoniaePneumococcal diseaseVaccine serotypesIncidence of IPDImplementation of PCV13Common clinical presentationIntroduction of PCV13Overall mortality rateChildhood immunization scheduleChildren 6 yearsProportion of casesMA childrenEnhanced surveillance systemIPD incidenceMerck vaccineIPD casesConjugate vaccinePCV13 eraClinical presentationComorbid conditionsImmunization schedule